Melanoma

This issue of Emerging Cancer Therapeutics provides a comprehensive review for practitioners on the current status of melanoma treatment. Due to recent drug approvals and increasing ability to offer combined agents, there are many more treatment options available to melanoma patients than even a few years ago. Especially significant are the recent FDA approval of the immunotherapeutic agent ipilimumab for metastatic melanoma, and new agents targeting the BRAF gene in malignant melanoma (these two developments cited among the top 5 most significant advances in oncology for 2011). There is also coverage of the most recent data pertaining to surgical management, staging and prevention, and melanoma in children. The authorship of the articles is outstanding and represents national and global authorities on the topics reviewed.